We directly investigated the frequency of YAP1 copy number amplification in clinical series from different human tumor types and revealed YAP1 amplification in 4/25 (16%) cervical cancer samples, in 18/77 (23%) non small cell lung cancers (NSCLC), in 2/56 (3.6%), central nervous system tumors (CNS) and in 0/15 thyroid cancers (Figure 1d). This evidence concerns the gene YAP1 and thyroid gland carcinoma.